Interventional Glaucoma

The glaucoma specialist spoke about his ESCRS agenda–and his calendar for 2024

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

Patients with HTG had significantly fewer mtDNA copies per nuclear DNA.

As part of the meeting’s MIGS programme, Keith Barton, MD, FRCP, FRCS, FRCOphth, shared data from the iTrack™ Global Data Registry

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

According researchers at the University of Gothenburg, for patients who recently received a diagnosis, discovery of glaucoma could mean they start treatment with daily eye drops that lower the pressure in the eye and slow down the damage to the optic nerve.

The trial is for the MINIject MIGS device for patients with primary open-angle glaucoma.

The system is a next generation aqueous shunt therapy for patients with moderate to severe glaucoma.

The company announced new data on outcomes for both open and narrow angle glaucoma patients.

According to the company, the deal expands its European footprint into Spain and Portugal.

Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

Oluwatosin U. Smith, MD, shares why she is excited for the conference and why it is relevant for today’s ophthalmologists and optometrists.

Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of omidenepag isopropyl ophthalmic solution in the United States.

Hundreds of previously-unknown genes could be vital for early detection and treatment.

According to the company, the financing will advance novel treatments for glaucoma and other chronic ophthalmic diseases by supporting multiple US clinical trials of its drug delivery platform.

The second issue of the 2023 Video Journal of Cataract, Refractive, & Glaucoma Surgery offers a compilation of 27 surgical highlights from the ESCRS meeting in Milan, providing valuable education for global anterior segment surgeons.

The company announced its contract manufacture, NextPharma, completed filling of the drug materials into strips of 10 single-use vials for use in upcoming glaucoma trial.

The open-access tool is the official registry partner of the European Glaucoma Society.

Procedures in the pipeline hold greater appeal for cataract and refractive surgeons, patients.

Preliminary results indicate significant improvement for patients and ‘very good safety profile’

The company seeks to replicate European success of the ELIOS procedure in the US market.

The funds will be used to further develop the company’s Calibreye System that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.

According to researchers, the study is the first to assess associations between pre-diagnostic circulating metabolites and POAG risk in two large independent datasets.